Highlights Arvinas, Inc.

Equities

ARVN

US04335A1051

Real-time Estimate Cboe BZX Other stock markets 11:08:51 2024-05-21 am EDT			5-day change	1st Jan Change
33.7 ^USD	+1.31%		+7.40%	-18.17%

May. 16	Sector Update: Health Care Stocks Steady Premarket Thursday	MT
May. 16	Sector Update: Health Care	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Steady Premarket Thursday	May. 16	MT
Sector Update: Health Care	May. 16	MT
Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity	May. 16	MT
Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity	May. 16	MT
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib	May. 16	CI
Arvinas Shares Up After Q1 Net Loss Narrows	May. 07	MT
Earnings Flash (ARVN) ARVINAS Reports Q1 Revenue $25.3M	May. 07	MT
Arvinas, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	Apr. 12	MT
Novartis: licensing agreement in prostate cancer	Apr. 11	CF
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis	Apr. 11	MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact	Apr. 11	DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion	Apr. 11	RE
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer	Apr. 11	CI
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue	Feb. 27	MT
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Arvinas, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
North American Morning Briefing : S&P 500 Seen -2-	Feb. 16	DJ
Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy	Feb. 06	CI
Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program	Dec. 05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arvinas, Inc.

Equities

ARVN

US04335A1051

Highlights

Filters